| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | CORT | Common Stock | Tax liability | -$13.8K | -228 | -0.27% | $60.58 | 85.1K | Mar 3, 2025 | Direct | F1, F2, F3 |
| transaction | CORT | Common Stock | Award | $15.7K | +266 | +0.31% | $59.07 | 85.4K | Mar 3, 2025 | Direct | F3, F4, F5 |
| transaction | CORT | Common Stock | Award | $0 | +266 | +0.31% | $0.00 | 85.6K | Mar 3, 2025 | Direct | F3, F6 |
| transaction | CORT | Common Stock | Options Exercise | $92.4K | +18.3K | +21.38% | $5.05 | 104K | Mar 3, 2025 | Direct | F3 |
| transaction | CORT | Common Stock | Sale | -$1.11M | -18.3K | -17.61% | $60.69 | 85.6K | Mar 3, 2025 | Direct | F3, F7, F8 |
| holding | CORT | Common Stock | 10K | Feb 28, 2025 | See Footnote | F9 | |||||
| holding | CORT | Common Stock | 10K | Feb 28, 2025 | See Footnote | F10 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | CORT | Stock option (right to buy) | Award | $0 | +140K | $0.00 | 140K | Feb 28, 2025 | Common Stock | 140K | $60.58 | Direct | F11 | |
| transaction | CORT | Stock option (right to buy) | Options Exercise | $0 | -18.3K | -12.89% | $0.00 | 124K | Mar 3, 2025 | Common Stock | 18.3K | $5.05 | Direct | F12 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. |
| F2 | The closing price on February 28, 2025 was used to calculate the withholding obligation. |
| F3 | Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024 and 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. |
| F4 | The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on March 3, 2025. |
| F5 | In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. |
| F6 | Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. |
| F7 | This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on September 5, 2024 in effect at the time of this transaction. |
| F8 | Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $60.58 to $61.055 per share. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. |
| F9 | Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. |
| F10 | Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee. |
| F11 | Exercise ratably in equal installments on each monthly anniversary of February 28, 2025 over a four-year period subject to the Reporting Person's continued service through each vesting date. |
| F12 | Fully exercisable. |
President, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission.